Drugs / Divaza
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03485495 | Apr 2018 → Apr 2019 | cerebral atherosclerosis | Materia Medica Holding | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Divaza | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03485495 ↗ |
| Route | Oral | “Oral administration.” NCT03485495 ↗ |